Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.
Augusto Villanueva,Augusto Villanueva,Yujin Hoshida,Yujin Hoshida,Carlo Battiston,Victoria Tovar,Victoria Tovar,Daniela Sia,Daniela Sia,Clara Alsinet,Clara Alsinet,Helena Cornella,Helena Cornella,Arthur Liberzon,Masahiro Kobayashi,Hiromitsu Kumada,Swan N. Thung,Jordi Bruix,Jordi Bruix,Philippa Newell,Craig April,Jian-Bing Fan,Sasan Roayaie,Vincenzo Mazzaferro,Myron Schwartz,Josep M. Llovet +25 more
TLDR
A composite prognostic model for HCC recurrence is developed, based on gene expression patterns in tumor and adjacent tissues, which predict early and overall recurrence in patients with HCC, and complement findings from clinical and pathology analyses.About:
This article is published in Gastroenterology.The article was published on 2011-05-01 and is currently open access. It has received 375 citations till now.read more
Citations
More filters
Journal ArticleDOI
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle,Alejandro Forner,Josep M. Llovet,Vincenzo Mazzaferro,Fabio Piscaglia,Jean-Luc Raoul,Peter Schirmacher,Valérie Vilgrain +7 more
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer
Josep M. Llovet,Michel Ducreux,Riccardo Lencioni,Adrian M. Di Bisceglie,Jean-Francois J. DuFour,Tim F. Greten,Eric Raymond,Tania Roskams,Vincenzo Mazzaferro,Jordi Bruix,Massimo Colombo,Andrew X. Zhu +11 more
TL;DR: The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data.
Journal ArticleDOI
Hepatocellular carcinoma: clinical frontiers and perspectives
TL;DR: While several trials have failed to improve the benefits of established therapies, studies assessing the sequential or combined application of those already known to be beneficial are needed to help explain the failure of prior studies.
Journal ArticleDOI
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.
Jessica Zucman-Rossi,Augusto Villanueva,Jean-Charles Nault,Jean-Charles Nault,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet +6 more
TL;DR: Data from genomic profiling enabled a proposal of HCC in 2 major molecular clusters (proliferation and non Proliferation), with differential enrichment in prognostic signatures, pathway activation and tumor phenotype, which helps define some of the core deregulated pathways in HCC.
Journal ArticleDOI
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Daniela Sia,Augusto Villanueva,Scott L. Friedman,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet +5 more
TL;DR: Proposals of the cell of origin of liver tumorigenesis are reviewed and the classes of liver cancer based on molecular features are clarified and how they affect patient prognosis are clarified.
References
More filters
Journal ArticleDOI
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Aravind Subramanian,Pablo Tamayo,Vamsi K. Mootha,Sayan Mukherjee,Benjamin L. Ebert,Michael A. Gillette,Amanda G. Paulovich,Scott L. Pomeroy,Todd R. Golub,Eric S. Lander,Jill P. Mesirov +10 more
TL;DR: The Gene Set Enrichment Analysis (GSEA) method as discussed by the authors focuses on gene sets, that is, groups of genes that share common biological function, chromosomal location, or regulation.
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
Cancer Statistics, 2009
TL;DR: The most recent data on cancer incidence, mortality, and survival from the American Cancer Society (ACS) is presented in this paper, where the authors compare the three major cancer sites in men (lung, prostate, and colon and rectum [colorectum]) and in two major cancers sites in women (breast and colorectal) over a 15-year period.
Related Papers (5)
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
Yujin Hoshida,Augusto Villanueva,Masahiro Kobayashi,Judit Peix,Derek Y. Chiang,Amy L. Camargo,Supriya Gupta,Jamie Moore,Matthew J. Wrobel,Jim Lerner,Michael R. Reich,Jennifer A. Chan,Jonathan N. Glickman,Kenji Ikeda,Masaji Hashimoto,Goro Watanabe,Maria Grazia Daidone,Sasan Roayaie,Myron Schwartz,Swan N. Thung,Helga B. Salvesen,Stacey Gabriel,Vincenzo Mazzaferro,Jordi Bruix,Scott L. Friedman,Hiromitsu Kumada,Josep M. Llovet,Todd R. Golub +27 more
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more